ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0926

Comparative Effectiveness Between Novel Medium Cut-Off Membrane Hemodialysis and Mixed-Dilution Online Hemodiafiltration on Middle Molecule Uremic Toxins Reduction: A Prospective Cross-Over Study

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Eiamcharoenying, Jirarat, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
  • Chariyavilaskul, Pajaree, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
  • Takkavatakarn, Kullaya, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
  • Susantitaphong, Paweena, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
  • Avihingsanon, Yingyos, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
  • Eiam-Ong, Somchai, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
  • Tiranathanagul, Khajohn, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
Background

Mixed-dilution online hemodiafiltration(mixed HDF), one of the best hemodialysis(HD) modes, provides superior removal of middle molecule uremic toxins to standard HD using high flux dialyzer. Due to the limited availabilities and high cost of HDF, we performed standard HD utilizing a novel medium cut-off membrane with a larger pore size and compared the effectiveness in removal of middle molecule uremic toxins with mixed HDF.

Methods

A prospective cross-over randomized controlled trial was conducted in 14 prevalent HDF patients who were randomly allocated into group1 (n=7): mixed-dilution online HDF with high flux dialyzer ELISIO21H and group2 (n=7): standard HD with MCO membrane, Theranova 500. In this 8-week study, the primary outcome was a reduction ratio(RR) of Beta2-microglobulin (B2M). Other small to middle molecules and protein-bound uremic toxins reduction ratio, dialysate albumin loss, and nutritional parameters were also compared.

Results

In this 8-week study, B2M RR from both modalities was higher than the survival benefit cut-point of 80%. In comparison, B2M RR was slightly lower but significant in MCO HD than mixed HDF (82.57+5.34% vs 85.12±3.87%, respectively) with the mean difference of 2.55 (95% confidence interval [CI], -4.07 to -1.03; P=0.001). The spKt/Vurea and URR, a small uremic toxin removal marker, were comparable. κFLC and Indoxyl sulfate RR also were similar in mixed HDF and MCO HD. Whereas RR of the larger middle molecule uremic toxin, Alpha1M and λFLC was lower with mixed HDF compare to MCO HD (30.13+15.90 vs 41.49+11.46 and 40.85+13.92 vs 50.81+13.18, respectively; P <0.001). Dialysate albumin loss was 3.51 g/session with MCO HD and 0.58 g/session with mixed HDF (P=0.025). Regarding, nutritional parameter, serum albumin levels were not different.

Conclusion

Mixed HDF and MCO HD provided the RR values of B2M and small uremic toxins above the recommended cut-point. Despite mixed HDF provided higher B2M RR, MCO HD also provided more performance in the clearance of the larger middle molecules, particularly a1M and λFLC. However, mixed HDF loss lower albumin than MCO HD. Therefore, both techniques can be used as alternative options.

Funding

  • Government Support – Non-U.S.